Company Filing History:
Years Active: 2014-2024
Title: The Innovative Contributions of Wenji Li
Introduction
Wenji Li is a prominent inventor based in Shanghai, China. He has made significant contributions to the pharmaceutical field, particularly in the development of novel compounds and their crystalline forms. With a total of nine patents to his name, his work has had a considerable impact on drug development and therapeutic applications.
Latest Patents
Wenji Li's latest patents include innovative formulations that target specific biological pathways. One notable patent is for crystalline forms of (s)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile, which serves as an inhibitor of phosphatidylinositol-3-kinase. This invention provides various crystalline forms, solvates, and pharmaceutical compositions, along with methods for their preparation and use. Another significant patent involves the pharmaceutically acceptable salts of the compound (S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine, which also includes its crystalline forms and methods of preparation.
Career Highlights
Wenji Li has worked with notable companies in the pharmaceutical industry, including Hutchison Medipharma Limited and Hutchmed Limited. His experience in these organizations has allowed him to contribute to various innovative projects and advancements in drug development.
Collaborations
Throughout his career, Wenji Li has collaborated with esteemed colleagues such as Zhenping Wu and Ling Feng. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Wenji Li's contributions to the pharmaceutical field through his patents and collaborations highlight his role as a key innovator. His work continues to influence the development of new therapeutic agents and improve patient outcomes.